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Abstract 
Monodermal teratomas of the ovary can take
the form of carcinoid tumors of which there
are several types, mucinous carcinoid being
the least common. Very few cases of primary
mucinous carcinoid of the ovary have been
reported in the literature and the behavior of
these tumors over the long term is unclear. We
describe a case of primary mucinous carcinoid
of the ovary in a 39-year-old woman treated
with unilateral salpingo-oophorectomy, where
a metastasis occurred in the contralateral
ovary ten years later. This case demonstrates
that mucinous carcinoid of the ovary can
metastasize even after a long interval, and
careful follow-up of patients, particularly those
treated conservatively, is appropriate. 
Introduction 
Fewer than thirty cases of primary mucin -
ous carcinoid of the ovary have been described
in the literature and the clinical behavior of
this tumor has not been well defined.1,2 We
describe a patient treated by unilateral
oophorectomy who presented with a metasta-
sis in the contralateral ovary more than ten
years later.
Case Report 
A 39-year-old woman presented with weight
loss and abdominal distention and was found
to have a pelvic-abdominal mass. Her previous
history included an appendectomy 27 years
earlier and a negative laparoscopy four years
previously. At laparotomy there was a 10 cm
mass originating from the left ovary, and a left
salpingo-oophorectomy was performed. The
uterus and right ovary appeared normal at
operation, as did the peritoneum, liver,
diaphragm, and lymph nodes. A diagnosis of
mucinous carcinoid of the left ovary was made
after postoperative gastroscopy, computer
tomography (CT) scan, mammography, ultra-
sound scan of the liver, and urine test for the
serotonin metabolite 5-HIAA proved negative.
In the light of these negative findings, and
given a strong desire on the part of the patient
for children, a decision was made to treat her
conservatively.
The patient was followed up for ten years
but shortly after, now 49 years old, she present-
ed with constipation and abdominal discom-
fort. A CT scan showed a mass measuring
15¥10 cm originating from the right ovary. A
right salpingo-oophorectomy and partial omen-
tectomy were performed; no abnormalities
were seen on the peritoneum, liver, or
diaphragm at operation and there was no obvi-
ous lymph node swelling. A histological diag-
nosis of metastatic mucinous carcinoid was
made. Currently, five years after the second
laparotomy, the patient remains well.Pathological findings Macroscopic appearances
The first tumor, from the left ovary, weighed
394 g and measured 9.0 cm in maximum diam-
eter (sampled in nine blocks). The cut surface
was partly solid and homogeneous with a light
brown color and partly cystic. The right ovarian
tumor, removed ten years later, was 19 cm in
diameter and weighed 1900 g (sampled in 20
blocks). This lesion was predominantly cystic,
with a solid area of 5 cm in diameter. Microscopic appearances 
The original tumor from the left ovary
showed predominantly small, round glands
lined by cells with globules of intracytoplasmic
mucin, lying in a collagenous stroma (Figure
1A) or floating in lakes of mucin. In most of the
tumor the epithelial cell nuclei were small and
basal with not more than mild atypia (Figure
1B). In some areas, however, the glands were
lined with more obviously atypical cells (Figure
1C). Here the glands lay closer together, some-
times abutting on one another. In one area
there were smaller glands with some cell nests
and individual signet ring cells. There was no
severe cytological atypia, solid growth of tumor
cells or necrosis. An occasional cystic space
was present lined by goblet cells with some
stratification. Mitotic activity in the more atyp-
ical areas reached 10 mitoses per 10 HPF.
Elsewhere in the tumor the mitotic rate was
lower but varied, with some areas showing 6
mitoses per 10 HPF. 
The metastatic tumor from the right ovary
showed round glands with an epithelial lining
that included goblet cells. Between the goblet
cells cylindrical cells with granular eosino -
philic cytoplasm were present. Occasionally
there were glands with small basal nuclei with
mild atypia, but in most areas the glands
showed a moderate epithelial atypia (Figure
2). In some areas the glands lay closer to -
gether, but nowhere was there a confluent
growth pattern or cribriform growth. There
were no solid areas. Individual signet ring cells
in the stroma were not a feature of this tumor.
The cysts seen macroscopically were a prom -
inent feature and were lined by the same cell
population as the small glands, often with
multi layering (Figure 2). Fairly extensive
areas of necrosis were present, involving
glands and stroma and interpreted as infarc-
tion rather than true tumor necrosis. Mitotic
activity was focally brisk, 17 per 10 HPF. In nei-
ther of the specimens was there any other
tumor component (for example, struma or
other carcinoid type or mature teratoma com-
ponent) identified. No vascular or lymphatic
invasion was identified.Immunohistochemistry 
Epitope retrieval was heat-induced and the
buffer used was tris-EDTA, pH 9. Both tumors
showed positivity for chromogranin (Biogenics
LK2H10, 1;200). In the primary tumor, staining
varied from sporadic cells in some areas to
staining of several cells in every gland in other
areas. In the metastasis, almost all glands
showed staining, varying from a few cells to
50% of the cells in the gland (Figure 3A).
Synaptophysin (Dako M0776, 1:400) staining
was positive in occasional cells (<5%) in the
primary tumor (Figure 3B), but no positive
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cells were found in the metastasis. NSE (Dako
BBS/NC/V1H14, 1:50) and CD56 (Neomarker
123c3.D5, 1:25) staining were negative. Molecular biology 
To determine the relationship between the
two tumors, loss of heterozygosity (LOH)
analysis was performed. The area of the pri-
mary tumor showing the most cytological and
architectural atypia was selected for analysis.
Sixteen microsatellite markers on 12 different
chromosomes were investigated for LOH. With
four microsatellite markers on four different
chromosomes, LOH was observed. An identical
pattern of loss in both tumors was found with
two microsatellite markers, D8S133 on chro-
mosome 8p and AFMa086WG9 in intron1 of
the PTEN gene on 10q. In addition, there was
LOH identified only in the later tumor with
markers D11S419 on chromosome 11p and
D13S1307 on 13q. 
Discussion 
Mucinous carcinoid is an unusual tumor in
the ovary and has been described more often
as metastatic from the appendix than as a pri-
mary lesion.3-11 Distinguishing primary ovarian
carcinoid from metastatic carcinoid can be
very difficult. Primary carcinoids of the ovary
are generally unilateral. Metastatic carcinoids
are nearly always bilateral and scattered tumor
deposits are present throughout both ovaries.3
In the case we describe, the appendix had been
removed 27 years before the first ovarian
tumor occurred, effectively excluding the
appendix as the primary. After the initial sur-
gery, extensive investigation failed to reveal
any tumor elsewhere and no other primary has
manifest itself in the following 15 years. 
We regard the second ovarian tumor as a
metastasis, and not as a second primary, on
the grounds of the similar histological picture
and the findings of the molecular biology
analysis. Immunohistochemical staining for
chromogranin was positive, and there was
scanty staining for synaptophysin in the first
tumor. These immunohistochemical stains can
support neuroendocrine differentiation, but
are not specific for mucinous carcinoid. The
morphology is also of key importance. The fact
that two identical markers were lost points to
the tumors being the same entity. The new
abnormalities in the metastatic tumor would
represent further chromosomal abnormalities
acquired during the progression of the tumor.
Our patient did not receive adjuvant chem o -
therapy after her second operation, because
the literature suggests surgical resection of
recurrent disease for ovarian carcinoid
tumors,12,13 and to our knowledge there is no
clear literature on management of metastatic
mucinous carcinoid. 
The paucity of cases described in the litera-
ture means that the behavior of ovarian
mucin ous carcinoid is not clearly defined.
Baker et al.1 described 17 cases that they sub-
divided into three groups, initially character-
ized by them as grade 1, 2, and 3 but ultimate-
ly classified as well-differentiated, atypical,
and carcinoma arising in mucinous carcinoid,
in an attempt to conform to the terminology
used in appendiceal carcinoid. They then
attempted to correlate the histological type
with the behavior. These authors observed a
gradation in mitotic activity, cytological atypia,
and architectural abnormality along the spec-
trum of lesions they describe. They comment-
ed that although they found no metastases in
their “well-differentiated’’ or “atypical’’ cate-
Case Report
Figure 1. (A) Primary tumor
(left ovary): small round glands
sometimes floating in lakes of
mucin typified the primary
tumor (hematoxylin and eosin,
100X). (B) Glands with small
minimally atypical basal nuclei
predominated in this tumor
(hematoxylin and eosin,
400X). (C) In places there was
moderate cytological atypia
and some fusing of glands
(hematoxylin and eosin,
400X). 
Figure 2. Metastatic tumor
(right ovary). Glands showing
moderate cytological atypia
predominated in this tumor.
Note the cystic spaces lined by
stratified atypical epithelium
(inset) (hematoxylin and eosin,
200X).
Figure 3. Immunohistoche m -
istry in primary tumor and
metastatic tumor. (A) Meta -
static tumor (right ovary): cells
staining positively for chromo-
granin were present in most
glands (200X). (B) Primary
tumor (left ovary): scattered
cells stained positively with
synaptophysin, in a gland with
cytological atypia (400X).
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gories they nevertheless suspect that these
lesions have a low malignant potential. Two
cases were categorized as carcinoma arising
in mucinous carcinoid, both more than stage I,
and were fatal within one year. All other
patients, even within this category, were stage
I and remained well. No cases of late metasta-
sis were observed in this series.
Our case showed areas in the primary tumor
that probably can best be classified as atypical
according to the categorization of Baker et al.,1
although the bulk of the tumor was well differ-
entiated. The metastasis showed much more
widespread cytological atypia; however, the
severe cytological atypia, solid growth pattern,
and tumor-type necrosis described by Baker et
al1 in their examples of carcinoma arising in
mucinous carcinoid were not apparent. The
tumors we describe are difficult to place exact-
ly in the categories described by Baker et al.,1
but the atypical histological features coupled
with the prolonged clinical course seem to
match their suggestion of a spectrum of histo-
logical abnormality and clinical behavior in
these lesions. On the basis of the case
described here we suggest that any atypical
architecture or increased mitotic activity, even
focally, signals a need for caution in assessing
prognosis.
Take home messages: 
1. Primary mucinous carcinoid in the ovary
is a rare tumor and should be diagnosed
only after rigorous exclusion of a primary
elsewhere.
2. The course of the disease may be pro-
longed with metastases after many years.
3. Atypical architecture or increased mitotic
activity, even focally, signals a need for
caution in assessing prognosis.
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Chronic recurrent Gorham-Stout syndrome with cutaneous involvement
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Abstract 
Type IV osteolysis or Gorham-Stout syn-
drome is a rare condition characterized by
recurrent vascular tumors that disrupt normal
anatomical architecture. Gorham-Stout syn-
drome is most commonly associated with the
skeletal system with resulting replacement of
bone with scar tissue following tumor regres-
sion. The loss of entire bones has given
Gorham-Stout syndrome the moniker vanish-
ing bone disease. Natural progression of
Gorham-Stout syndrome is characterized by
spontaneous disease resolution. However, rare
variants of recurrent, progressive, and/or sys-
temic disease have been reported. We present
a patient with a history of recurrent Gorham-
Stout disease refractory to all treatment
options considered. In addition to skeletal dis-
ease, our patient had soft tissue and cuta-
neous involvement, thus reflecting the more
aggressive disease variant. Previous surgical
attempts to control disease had been ineffec-
tive and the patient was referred to us for radi-
ation therapy. Treatment with external beam
radiation therapy resulted in good local control
and symptom palliation, but full disease reso-
lution was never accomplished. In addition to
presentation of this patient, a review of the lit-
erature on etiological hypotheses and
past/future treatment options was conducted
and is included.
Introduction
Type IV osteolysis or Gorham-Stout syn-
drome is a rare variant of idiopathic osteolytic
disease.1 In 1838 Jackson first described the
disease in an 18-year-old man with a gradually
vanishing humerus.2 Later, in 1955 Gorham
and Stout identified and reported 16 patients
with similar disease.3 Gorham-Stout syndrome
is characterized by progressive angiomatosis
of venous, capillary, or lymphatic origin.4-6 The
pathology of Gorham-Stout syndrome is associ-
ated with angiomatosis coupled with active
osteolysis resulting in vascular tumor replace-
ment of bone. The osteolysis can be monostot-
ic or polyostotic and has the potential to result
in the physical loss of entire bones – hence the
term “vanishing bone disease.” Involution and
resolution, whether spontaneous or treatment
induced, will result in replacement of the
lesion with connective tissue; thus changing
the underlying anatomy and physiology of the
region. Often, presentation of Gorham-Stout
syndrome is a consequence of the comprom -
ised skeletal framework.1,7 Anatomical malfor-
mations and pathological fractures are often
seen as common symptoms of presentation.
Other presenting signs or symptoms are asso-
ciated with underlying inflammation, such as
fatigue and generalized pain.7 Diagnosis is a
combination of clinical suspicion with support-
ive imaging, but is confirmed by histopatholog-
ical analysis of the lesions. Biopsy always
shows extensive nonmalignant hyperprolifera-
tion of small vessels.1,5,7
Gorham-Stout SyndromeReview
Gorham-Stout syndrome has been described
in all anatomical locations and tissue types,
but is seen most commonly in the anatomical
girdles (pelvic or shoulder) or in the long
bones of the extremities. Rarely, soft tissue or
skin lesions are seen and their presence
reflects an increased severity of disease. One
review noted that only five of the 220 (2.27%)
reported cases of Gorham-Stout syndrome had
cutaneous involvement in their disease.5 When
present, soft tissue lesions are reflective of
involved bone distribution.5
Patient age ranges have been reported from
one month to 75 years,1 with children and
young adults being most commonly afflicted.
To date, there has not been an epidemiologic
correlation with race, gender, or geography.7-10
Originally, Gorham and Stout postulated the
tumors to be secondary to progressive hem -
angiomatosis.3,10 The etiology is largely
unknown but is thought to be multifactorial.
Review of current literature yielded many pos-
sible etiological factors. In summary, Gorham-
Stout syndrome is thought to result from a
complex interaction between growth factors,
angiogenic factors, and inflammatory media-
tors. A previous study identified histological
markers on the characteristic cells of Gorham-
Stout syndrome that indicate a monocyte line-
age.11 These so-called Gorham cells (GCs) have
been shown to respond to known osteoclastic
and angiogenic factors resulting in disease
specific pathology. In particular, vascular
endothelial growth factor (VEGF) subtypes,
platelet-derived growth factor subtypes
(PDGF), and inflammatory cytokines (TGF, IL-
6, and IL-1) lead to increased activity of the
GCs.11,12 In 2006 Bruch-Graher and colleagues
argued a lymphatic origin of the angiomatosis
leading to lesion formation.5,10 A publication
written by Hagendoorn et al. emphasized the
evidence supporting lymphatic vasculature as
the tissue of origin for Gorham-Stout syn-
drome tumors. Hagendoorn et al. found that
the majority of endothelial cells in the lesions
expressed a surface protein indicative of
lymph atics, lymphatic vascular endothelial
hyaluronan receptor-1 (LYVE-1).4,13 In concord -
ance with previously reported findings,
Hagendoorn et al. identified high circulating
levels of VEGF and PDGF subtypes.11,13
The majority of cases reported show
spontan eous resolution of disease for
unknown reasons.4,14,15 However, rare cases of
chronic recurrent angiomatosis have been
reported, many ultimately resulting in death.
Chylothorax and spinal cord compression are
two of the more severe examples of complica-
tions resulting from chronic disease.
Chylothorax results from occlusion of the large
lymphatic vessels in the thorax and in turn
leads to fluid collection.5,10,11 Osseous degener -
ation of the vertebrae leads to skeletal frame-
work compromisation and spinal cord com-
pression. Prompt therapeutic intervention is
recommended with evidence of lymphatic or
vertebral invasion.1,7,10,16,17
There is no known cure for Gorham-Stout
syndrome and as such treatment depends on
patient specific variables. Historically, local
control was the primary therapeutic goal for
recurrent disease. Classically, local disease
was managed with a combination of surgical
resection or radiation therapy.10,18-21 Investi -
gation of the literature indicates radiotherapy
to be the best option to halt disease progres-
sion, with reported results showing foci of
bone regrowth.7,10,18-21 Investigation into the
pathophysiology behind Gorham-Stout syn-
drome has resulted in an evolution in treat-
ment options targeting proposed pathophysio-
logical pathways. For example, bisphosphonate
therapy has been shown to decrease osteolytic
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